About Us - BrightGene Health

Development History

2001

BrightGene was formally established.

2006

Develop an entecavir synthesis process with independent rights

2010

Completed Series A financing and Lilly Asia Ventures became a shareholder.
Established a wholly-owned subsidiary, Xintai Pharmaceuticals.
Acquired Jiangsu Senran Chemical.
Acquired Chongqing Qiantai Biology.

2012

Completed Series B financing of 60 million yuan, led by Lilly;
The wholly-owned subsidiary Xintai Pharmaceutical was built

2015

Completed Series C financing of 150 million yuan, with CICC investing;Completed the joint-stock reform;Xintai
Pharmaceutical passed the new domestic GMP certification in China

2017

Completed Series D financing, with SDIC and Huatai investing;
Passed the official certification of Japan's PMDA for the first time;
Passed the inspection of the US FDA with "zero defect"

2018

Registered and established the Hong Kong subsidiary;
Registered and established the BrightGene Indonesia grand-subsidiary;
Registered and established the BrightGene Europe grand-subsidiary;
Three products passed the EU GMP certification;
Completed a financing of 550 million yuan, with Sequoia and Horizon investing

2019

On November 8th:
Listed on the STAR Market;
Entecavir Tablets were approved by ANDA in the United States;
Fondaparinux Sodium Injection was approved for listing

2020

The foundation-laying ceremony of BrightGene's global headquarters was a complete success.
The BrightGene Healthcare was established, focusing on the R&D and commercialization by synthetic biology

2021

BrightGene made the list of top 50 values of the STAR Market with its strength;
Oseltamivir Phosphate Capsules (Meishulun®) were approved for listing

2023

BrightGene was listed the top 100 innovative private enterprises in Suzhou in 2022;
Argatroban Injection was approved for listing;
Oseltamivir Phosphate Dry Mix was approved for listing

Closed-loop Business Ecosystem

Holypharm + LaurelVenture
Seeking the oppotunities driven by systhetic biology around the world.

LaurelVenture + BrightGene
Industrial Fund participation in project early layout
Special Fund empowers project incubation and future mergers and acquisitions

BrightGene Research Institutes
Fermentation Research Institute focusesion strain construction and expression synthesis.
Chemical Research institute focuses on product isolation and purification.

TaiXing , ChongQing, ShanDong, Overseas site
Different production bases meet different products and scale up commercial production.

BrightGene Health
BrightGene Health leads market development, meanwhile BrightGene provides collaborative support to jointly serve global customers.

Core R&D Strength

BrightGene Health builds on decades of microbial research and development achievements from BrightGene Bio-Medical. Adhering to the principle of independent innovation, it places great emphasis on research and creation, having established a leading industry synthetic biology research and development center. This center is dedicated to developing and building a new platform for microbial screening and construction, aiming to drive growth and innovation in the field of biosynthesis.

Team: 83 R&D person, 86% of them are bachelor degree or above.

Platform: Fully autonomous chassis cell database; Fully autonomous editing tool for screening models

Hardware Support: Research institute has a laboratory area of over 5000 m², with high price advanced analytical equipment like NMR,ICP-MS, & 400M NMR

Investment: Continuous high R&D investment every year, with a cumulative R&D investment reaching 180 million yuan.

Equipment List

Certification System and Audit Qualifications

page-1600-660

Intellectual Property Rights

page-1600-628

Business and Innovation

Synthetic Biology Drives Innovative Development in Biopharmaceuticals, Personal Care, and Nutritional Supplements.

Pharmaceuticals

Intermediates; APIs; Preparations; Drug-device combination. Delievery technology platform.

Personal Care

Bio-Active Ingredients, Formulations, Enhancing technology.

Nutritional Supplements

Bio-Active Ingredients,Oral-delievery technology.

Business and Innovation

The company has invested in a large-scale fermentation production line with an annual capacity of hundreds of tons of active ingredients, which is now fully operational. The first project to utilize a fully biological synthesis method, copper peptide, was commercialized and put into production in the third quarter of 2023, with total annual capacity expected to exceed 2 tons in 2024. The company has also assembled a professional team focused on the global active ingredients market. The business has expanded rapidly, achieving partnerships and channel development with hundreds of global brands.